Photocure Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 3/6

Photocure şirketinin kazançları yıllık ortalama -18.9% oranında azalırken, Pharmaceuticals sektörünün kazançları yıllık 1.2% oranında artan oldu. Gelirler yıllık ortalama 15.9% oranında artan oldu. Photocure şirketinin öz sermaye getirisi 2.8% olup, net marjı 2.7% dir.

Anahtar bilgiler

-18.9%

Kazanç büyüme oranı

-19.3%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi	6.0%
Gelir büyüme oranı	15.9%
Özkaynak getirisi	2.8%
Net Marj	2.7%
Son Kazanç Güncellemesi	30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Photocure nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

OTCPK:PHCU.F Gelir, gider ve kazançlar (NOK Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Sep 24	526	14	361	4
30 Jun 24	514	13	355	3
31 Mar 24	512	5	350	2
31 Dec 23	501	1	348	2
30 Sep 23	462	-34	346	2
30 Jun 23	462	-39	342	2
31 Mar 23	418	-62	329	3
31 Dec 22	393	-72	319	3
30 Sep 22	383	-79	307	4
30 Jun 22	364	-76	299	4
31 Mar 22	354	-68	289	5
31 Dec 21	361	-31	275	4
30 Sep 21	364	7	261	7
30 Jun 21	326	9	233	10
31 Mar 21	290	10	214	11
31 Dec 20	256	-22	201	14
30 Sep 20	274	10	178	14
30 Jun 20	285	15	174	13
31 Mar 20	284	19	165	13
31 Dec 19	282	32	160	14
30 Sep 19	216	-23	153	15
30 Jun 19	199	-27	147	16
31 Mar 19	192	-39	140	18
31 Dec 18	182	-37	132	19
30 Sep 18	171	-38	123	23
30 Jun 18	162	-43	170	42
31 Mar 18	156	-31	114	28
31 Dec 17	151	-35	108	33
30 Sep 17	150	-4	103	32
30 Jun 17	149	6	45	13
31 Mar 17	145	29	92	27
31 Dec 16	144	35	90	23
30 Sep 16	140	8	91	25
30 Jun 16	141	3	91	26
31 Mar 16	140	-26	87	30
31 Dec 15	135	-36	84	31
30 Sep 15	126	-58	53	31
30 Jun 15	147	-29	57	31
31 Mar 15	138	-23	59	31
31 Dec 14	129	-25	64	33
30 Sep 14	129	-2	65	33
30 Jun 14	92	-39	65	34
31 Mar 14	89	-50	71	34
31 Dec 13	84	-59	76	34

Kaliteli Kazançlar: PHCU.F yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: PHCU.F geçmişte karlı hale geldi.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: PHCU.F son 5 yılda karlı hale geldi ve kazançlarını yıllık -18.9% oranında artırdı.

Büyüme Hızlandırma: PHCU.F son bir yılda karlı hale geldi, bu da kazanç büyüme oranının 5 yıllık ortalamayla karşılaştırılmasını zorlaştırıyor.

Kazançlar vs. Sektör: PHCU.F son bir yılda karlı hale geldi ve bu durum, geçmiş yıl kazanç büyümesinin Pharmaceuticals sektörüyle ( 54.6% ) karşılaştırılmasını zorlaştırıyor.

Özkaynak Getirisi

Yüksek ROE: PHCU.F 'nin Özsermaye Getirisi ( 2.8% ) düşük olarak değerlendiriliyor.

Photocure Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 3/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Photocure ASA to Report Q4, 2023 Results on Feb 21, 2024

Photocure ASA to Report First Half, 2023 Results on Aug 09, 2023

Photocure ASA to Report Q3, 2021 Results on Nov 17, 2021

Recent updates

Photocure ASA Announces Board Appointments

Photocure ASA Reiterates Financial Guidance for the Year 2024

Photocure ASA Announces Pivotal Trial Results and New Real-World Evidence

Photocure ASA Announces the Publication of the Study Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy

Photocure ASA to Report Q4, 2023 Results on Feb 21, 2024

Photocure ASA Partner Asieris Announces New Drug Application Acceptance for Regulatory Review of Hexvix in China

Photocure ASA Announces Change of Board Composition

Photocure Partner Asieris Confirms Hexvix Phase III Clinical Trial in China Meets Endpoint

Photocure Partner Asieris Announces Completion of Enrollment for Hexvix Phase III Clinical Trial in China

Photocure Asa Announces Clinical Data Presented At ASCO GU Demonstrates Reduced Risk of Recurrence in Non-Muscle Invasive Bladder Cancer with the Use of BLC

Photocure Asa Announces the Publication of the Study "Clinical and Economic Impact of Blue Light Cystoscopy in the Management of Nmibc At U.S. Ambulatory Surgical Centers: What Is the Site-Of-Service Disparity?" in Urologic Oncology This Week

Photocure Asa Announces the Publication of the Study "Clinical and Economic Impact of Blue Light Cystoscopy in the Management of Nmibc At U.S. Ambulatory Surgical Centers: What Is the Site-Of-Service Disparity?" in Urologic Oncology This Week

Photocure ASA to Report First Half, 2023 Results on Aug 09, 2023

Photocure ASA Announces New Evidence Presented At the 22nd Annual Society of Urologic Oncology Meeting Demonstrating That Blue Light Cystoscopy

Photocure Asa Announces Data Presented At the International Bladder Cancer Network (Ibcn) Meeting Demonstrate A Reduction in the Risk of Recurrence with the Use of Blc

PPhotocure ASA Announces the Commercial Availability of Karl Storz's New Blue Light System in the U.S

Photocure ASA Publishes First Results from Laser III Clinical Study in Medical Journal, European Urology

Photocure ASA Announces Continue E Supporting the Global Launch Activities of the New and Improved Blue Light Cystoscopy

Photocure ASA Appoints Anders Neijber as Chief Medical Officer, Global Medical Affairs and Clinical Development

Photocure Asa Provides Update on Anticipated Commercial Availability of Karl Storz's New Blue Light System in the United States

Photocure ASA Presents Positive Data from the Danish National Patient Registry at the 2022 NordUrologisk Forening (NUF) Congongress in Helsinki

Photocure ASA (OB:PHO) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on April 28, 2022.

Photocure Announces Endotherapeutics Group as New Commercial Partner for Hexvix in Australia & New Zealand

Photocure ASA Announces the Publication of Pre-Clinical Study Results Supporting the Anti-tumor Effect of Hexaminolevulinate with Blue Light in Bladder Cancer model

Photocure ASA Receives FDA Approval for Use in NMIBC in the U.S

Photocure ASA Announces the Publication of a Study in the Journal Urologic Oncology

Asieris Announces First Patient Administration in Europe within the Phase III Clinical Trial for APL-1702 (Cevira)

Photocure ASA (OB:PHO) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on June 10, 2020.

Photocure ASA Suspends Guidance for 2023

Photocure ASA to Report Q3, 2021 Results on Nov 17, 2021

Asieris Pharmaceuticals and Photocure ASA Expands Strategic Partnership to Bladder Cancer Diagnosis and Surgery in Mainland China and Taiwan

Photocure Partners with Asieris MediTech to Commercialize Hexvix in Mainland China and Taiwan

Photocure Announces New Cevira Patent In Europe

Photocure Launches European Hexvix Operations

Photocure ASA Provides Revenue Guidance for the Year 2020

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin